Condition
Primary Refractory Acute Myeloid Leukemia
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by Dreamland
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Recruiting2
Clinical Trials (2)
Research Network
Common Treatments
- Dreamland1
- Specialty Palliative Care1
- Primary Palliative Care1
- Vital Wellness1
Active Sponsors
- Massachusetts General Hospital2
- Patient-Centered Outcomes Research Institute1
- National Cancer Institute (NCI)1
Top Investigators
Massachusetts General Hospital
Massachusetts General Hospital
Related Conditions
- High Risk Acute Myeloid Leukemia2
- Relapsed Adult Aml1
- Relapsed Adult Acute Myeloid Leukemia1